推荐产品
等级
pharmaceutical primary standard
API类
warfarin
制造商/商品名称
USP
mp
162-164 °C (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O
InChI
1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
InChI key
PJVWKTKQMONHTI-UHFFFAOYSA-N
基因信息
human ... VKORC1(79001)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Warfarin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Warfarin Sodium
- Warfarin Sodium Tablets
- Warfarin Sodium for Injection
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
法律信息
警示用语：
Danger
危险分类
Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral
靶器官
Blood
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
非剧毒-急性毒性1
农药列管产品
Daisuke Yoshioka et al.
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 17(4), 308-314 (2014-07-23)
The aim of this study was to evaluate our clinical experience with the Jarvik 2000 axial flow pump (Jarvik Heart, Inc, New York, NY, USA), a miniature axial flow left ventricular assist device (LVAD). The clinical results of eight patients
Benjamin A Steinberg et al.
Circulation, 131(5), 488-494 (2014-12-17)
Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. The Outcomes Registry for Better Informed Treatment of
James D Douketis et al.
Thrombosis and haemostasis, 113(3), 625-632 (2014-12-05)
In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain.We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for
Hugh S Markus et al.
The Lancet. Neurology, 14(4), 361-367 (2015-02-17)
Extracranial carotid and vertebral artery dissection is an important cause of stroke, especially in young people. In some observational studies it has been associated with a high risk of recurrent stroke. Both antiplatelet drugs and anticoagulant drugs are used to
Tomasz Baron et al.
Heart (British Cardiac Society), 101(2), 101-106 (2014-10-22)
We aimed to assess differences in incidence, clinical features, current treatment strategies and outcome in patients with type 2 vs. type 1 acute myocardial infarction (AMI). All 20 138 hospitalisations in Sweden with a diagnosis of AMI registered during 2011 in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门